This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:
—In line with Dr. Bevan's address in regard to leaving German scientists and preparations alone and using American, I will state that "Aspirin Bayer" decreased in price from $8.80 to $4.40 per thousand at the time their patent expired, about eighteen months ago. The foregoing were prices I paid at that time, being a retail druggist. Physicians, not druggists, paid more. They were charging $4.40 per thousand above legitimate profit or they would not have reduced the price that amount when their protection expired. I wonder how many millions of these $4.40 went to help the kaiser.The government should protect a patentee (if not a Hun) but should not allow him to collect cost plus a legitimate profit and then double the charge.
Harris CH. UNRIGHTEOUS PROFITS IN PATENTED PRODUCTS. JAMA. 1918;70(26):2047. doi:https://doi.org/10.1001/jama.1918.02600260059018
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: